Design and Goals of the Phase 3 MOUNTAINEER-03 Study in mCRC
Tanios S. Bekaii-Saab, MD, FACP, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study.
Background of the MOUNTAINEER-03 Study in HER2+ Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD, FACP, discusses background that led to the start of the MOUNTAINEER-03 trial.
Next Steps for the MOUNTAINEER-03 Study in HER2+ Metastatic Colorectal Cancer
Tanios S. Bekaii-Saab, MD, FACP, discusses what to expect if data from the MOUNTAINEER-03 study are positive.
Evolution of Agents Targeting KRAS G12C Mutated Gastrointestinal Cancers
Tanios S. Bekaii-Saab, MD, FACP, discusses the evolution of treatment options prior to adagrasib for patients with KRAS G12C mutations.
Utilizing Adagrasib as Treatment of KRAS G12C-Mutated GI Malignancies
Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.
Adagrasib Shows High Response Rates in GI Cancers
Tanios S. Bekaii-Saab, MD, FACP, discusses the phase 1/1b and 2 KRYSTAL-1 trial and his presentation from the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.